Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-13T14:18:09.381Z Has data issue: false hasContentIssue false
  • English
  • Français

Data and Safety Monitoring Boards: Some Enduring Questions

Published online by Cambridge University Press:  01 January 2021

Charles J. Kowalski  and
Jan L. Hewett
Get access Rights & Permissions [Opens in a new window]

Extract

Data Safety and Monitoring Boards (DSMBs) were introduced in the 1960s to monitor data in clinical trials to ensure subject safety. It was thought important that DSMB members be experts in the field(s) of interest, but not otherwise involved in the study (e.g., sponsors and investigators) in order to maximize objectivity. Since then, the use of DSMBs has increased dramatically, and their scope has expanded to include scientific issues — in particular, to avoid bias that can result when trials are stopped early because of evidence that one treatment has greater efficacy or causes greater harm than another; or that no treatment is likely to do better than any other.

Type
Independent
Information
Journal of Law, Medicine & Ethics , Volume 37 , Issue 3 , Fall 2009 , pp. 496 - 506
Copyright
Copyright © American Society of Law, Medicine and Ethics 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

These are also known as Data Safety Committees (DSCs), Independent Data Monitoring Committees (IDMCs), Data Monitoring Committees (DMCs) and Data Review Boards (DRBs).Google Scholar
Tharmanathan, P., Calvert, M., Hampton, J. and Freemantle, N., “The Use of Interim Data and Data Monitoring Committee Recommendations in Randomized Controlled Trial Reports: Frequency, Implications and Potential Sources of Bias”, BMC Medical Research Methodology 8 (2008), available at <http://www.biomedcentral.com/1471-2288/8/12> (last visited July 20, 2009).CrossRefGoogle Scholar
Ellenberg, S. S., Fleming, T. R. and DeMets, D. L., Data Monitoring Committees in Clinical Trials (New York: Wiley, 2003).Google Scholar
Green, S. J., Fleming, T. R. and O'Fallon, J. R., “Policies for Study Monitoring and Interim Reporting of Results”, Journal of Clinical Oncology 5, no. 9 (1987): 1477–1484.CrossRefGoogle Scholar
Wells, R. J., Gartside, P. S. and McHenry, C. L., “Ethical Issues Arising When Interim Data in Clinical Trials Is Restricted to Independent Data Monitoring Committees”, IRB: A Review of Human Subjects Research 22, no. 1 (2000): 7–11.CrossRefGoogle Scholar
Edwards, S. J. L., Lilford, R. J. and Hewison, J., “The Ethics of Randomized Controlled Trials from the Perspectives of Patients, the Public and Healthcare Professionals”, BMJ 317, no. 4 (1998): 1209–1212.CrossRefGoogle Scholar
See Ellenberg, et al., supra note 3. One reason for this is that the NIH requires that a DSMB monitor every phase III trial.Google Scholar
Food and Drug Administration, Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees, Rockville, MD, 2005.Google Scholar
See Ellenberg, et al., supra note 3.Google Scholar
Meinert, C. L., “Clinical Trials and Treatment Effects Monitoring”, (with discussion), Controlled Clinical Trials 19 (1998): 515–543.CrossRefGoogle Scholar
Freedman, B., “Equipoise and the ethics of clinical research”, New England Journal of Medicine 317, no. 3 (1987): 141–145.CrossRefGoogle Scholar
Hellman, S. and Hellman, D. S., “Of Mice, but Not Men: Problems of the Randomized Clinical Trial”, New England Journal of Medicine 324, no. 22 (1991): 1589–1592.CrossRefGoogle Scholar
Lilford, R. J., Braunholtz, D., Edwards, S. S. and Stevens, A., “Monitoring Clinical Trials – Interim Data Should Be Publicly Available”, BMJ 323, no. 7310 (2001): 441–442.CrossRefGoogle Scholar
They cite the ISIS 2 example, where initially skeptical physicians moved into equipoise.Google Scholar
Both the NBAC and Beecher are quoted in Michels, R., “Are Research Ethics Bad for Our Mental Health?” New England Journal of Medicine 340, no. 18 (1999):1427–1430.CrossRefGoogle Scholar
Ingelfinger, F. J., “Informed (but Uneducated) Consent”, New England Journal of Medicine 287, no. 6 (1972): 465–466.CrossRefGoogle Scholar
Weijer, C., Shapiro, S. H., Fuks, A., Glass, K. C. and Skrutkowska, M., “Monitoring Clinical Research: An Obligation Unfulfilled”, Canadian Medical Association Journal 152, no. 12 (1995): 1973–1979.Google Scholar
Goodman, K. W., Ethics and Evidence-Based Medicine (Cambridge: Cambridge University Press, 2003).Google Scholar
By this is meant systematic reviews of the literature, aka metaanalysis.Google Scholar
Adams, M. S. and Conrad, D. A., “Annual Review: Observed Deficiencies and Suggested Corrections”, IRB: A Review of Human Subjects Research 18, no. 5 (1996): 1–6.CrossRefGoogle Scholar
Available at <www.hhs.gov/ohrp/humansubjects/guidance/contrev0107.htm> (last visited July 7, 2009).+(last+visited+July+7,+2009).>Google Scholar
Meinert, C. L., “Masked Monitoring in Clinical Trials – Blind Stupidity?” New England Journal of Medicine 338, no. 16 (1998): 1381–1382.CrossRefGoogle Scholar
Meinert, C. L., “IRBs and Randomized Clinical Trials”, IRB: A Review of Human Subjects Research 20, no. 1 (1998): 9–12.CrossRefGoogle Scholar
See Wells, et al., supra note 5.Google Scholar
To be fair, this is based on the pvalues 0.169 that by study's end A would be favored, and 0.00002 that B would be favored. The chance that neither would be favored is 0.8309.Google Scholar
Royall, R. M., “Ethics and Statistics in Randomized Clinical Trials”, (with discussion), Statistical Science 6, no. 1 (1991): 52–88.CrossRefGoogle Scholar
Veatch, R. M., “Comment”, Controlled Clinical Trials 19, no. 6 (1997): 532–533.Google Scholar
Tukey, J., “Conclusions vs. Decisions”, Technometrics 2, no. 4 (1960): 423–433.CrossRefGoogle Scholar
Veatch, R. M., “Longitudinal Studies, Sequential Design, and Grant Renewals: What to Do with Preliminary Data”, IRB: A Review of Human Subjects Research 1, no. 3 (1979): 1–3.CrossRefGoogle Scholar
Kadane, J. B., ed., Bayesian Methods and Ethics in a Clinical Trial Design (New York: Wiley, 1996).CrossRefGoogle Scholar
Hellman, D., “Evidence, Belief and Action: The Failure of Equipoise to Resolve the Ethical Tension in the Randomized Clinical Trial”, Journal of Law, Medicine & Ethics 30, no. 2 (2002): 375–380.CrossRefGoogle Scholar
Gifford, F., “Freedman's ‘Clinical Equipoise’ and ‘Sliding-Scale All-Dimensions-Considered Equipoise,’” Journal of Medicine & Philosophy 25, no. 4 (2000): 399–426.CrossRefGoogle Scholar
Chiong, W., “The Real Problem with Equipoise”, American Journal of Bioethics 6, no. 4 (2006): 37–47.CrossRefGoogle Scholar
Chiong suggested a rough-and-ready test for the universalizability of some practice: whether we would be willing to imagine ourselves, our loved ones, or our peers on the receiving end of some treatment. What would it be like if everybody did that?Google Scholar
Meier, P., “Statistics and Medical Experimentation”, Biometrics 31, no. 2 (1975): 511–529.CrossRefGoogle Scholar
Amdur, R. J., “Provisions for Data Monitoring”, in Amdur, R. J. and Bankert, E. A., eds., Institutional Review Board: Management and Function (Sudbury, MA: Jones and Bartlett, 2002): 191–196.Google Scholar
Wendler, D. and Rackoff, J., “Consent for Continuing Research Participation: What Is It and When Should It Be Obtained?” IRB: Ethics & Human Research 24, no. 2 (2002): 1–6.CrossRefGoogle Scholar
Miller, F. G. and Wendler, D., “Is It Ethical to Keep Interim Findings of Randomized Controlled Trials Confidential?” Journal of Medical Ethics 34, no. 4 (2008): 198–201.CrossRefGoogle Scholar
Beauchamp, T. L. and Childress, J. F., Principles of Biomedical Ethics, 5th ed. (New York: Oxford University Press, 2001).Google Scholar
Slutsky, A. S. and Lavery, J. V., “Data Safety and Monitoring Boards”, New England Journal of Medicine 350, no. 11 (2004): 1143–1147.CrossRefGoogle ScholarPubMed
Cannistra, S. A., “The Ethics of Early Stopping Rules: Who Is Protecting Whom?” Journal of Clinical Oncology 22, no. 9 (2004): 1542–1545.CrossRefGoogle Scholar
Menikoff, J., What the Doctor Didn't Say: The Hidden Truth about Medical Research (New York: Oxford University Press, 2006).
The consent form also failed to mention that that the patient could get the chemotherapy from a doctor, outside of the study, and thus be sure of getting this, instead of the 50% chance in the study. See id., at 130.Google Scholar
Veatch, R. M., “The Right of Subjects to See the Protocol”, IRB: Ethics & Human Research 24, no. 4 (2002): 6–8.CrossRefGoogle Scholar
Levine, R. J., Ethics and Regulation of Clinical Research, 2nd ed. (New Haven: Yale University Press, 1986).Google Scholar
This differs from the “reasonable person” standard, as described by Menikoff (supra note 42, at 92), who suggests that “…the appropriate standard for determining disclosure in the research setting should always be the reasonable person standard.” Beauchamp and Childress (supra note 2, at 327) thought DSMBs should “supply physicians and patients with significant safety and therapeutic information that is relevant to a reasonable person's decision to remain in or withdraw from the trial.” Reasonable people need not insist on statistical significance before they are willing to act.Google Scholar
Buchanan, D. and Miller, F. G., “Principles of Early Stopping of Randomized Trials for Efficacy: A Critique of Equipoise and an Alternative Nonexploitation Ethical Framework”, Kennedy Institute of Ethics Journal 2, no. 2 (2005): 161–178.CrossRefGoogle Scholar